Literature DB >> 15278277

[Heparin induced thrombocytopenia. A frequently unrecognised complication after major orthopedic surgery].

S M Picker1, B S Gathof.   

Abstract

The application of unfractioned (UFH) and low molecular weight heparins (LMH) has reduced the incidence of thromboembolic events. However, the frequency of heparin-induced thrombocytopenia (HIT II) in orthopedic patients, particularly susceptible for both thromboembolic complications and HIT II with potentially life threatening complications, is about 0.5% for LMW and 3% UFH. Induced by an immune response, the excessive activation of platelets and endothelial cells causes massive thrombin generation and, as a result, thrombotic vessel occlusion. The rates of mortality and amputation in HIT II are estimated to be 30% and 20%, respectively. The clinical course is highly dependent on early therapeutic intervention, consisting of compatible and adequately dosed anticoagulation drugs. Vitamin K antagonists as well as platelet substitution may lead to disastrous sequelae. We summarize the current state of the pathophysiology, diagnosis and therapy of HIT II and illustrate therapeutic mistakes in a case report.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15278277     DOI: 10.1007/s00132-004-0695-3

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  24 in total

Review 1.  [The diagnosis of heparin-associated thrombocytopenia].

Authors:  A Greinacher; C Mueller-Eckhardt
Journal:  Dtsch Med Wochenschr       Date:  1991-09-27       Impact factor: 0.628

Review 2.  Heparin-induced thrombocytopenia: towards consensus.

Authors:  T E Warkentin; B H Chong; A Greinacher
Journal:  Thromb Haemost       Date:  1998-01       Impact factor: 5.249

Review 3.  Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia.

Authors:  T E Warkentin
Journal:  Transfus Med Rev       Date:  1996-10

4.  Management of heparin induced thrombocytopenia.

Authors:  H N Magnani
Journal:  BMJ       Date:  1993-07-17

Review 5.  Heparin-associated thrombocytopenia.

Authors:  D J King; J G Kelton
Journal:  Ann Intern Med       Date:  1984-04       Impact factor: 25.391

6.  Characterization of the humoral immune response in heparin-induced thrombocytopenia.

Authors:  J S Suh; M I Malik; R H Aster; G P Visentin
Journal:  Am J Hematol       Date:  1997-03       Impact factor: 10.047

7.  Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.

Authors:  A Greinacher; P Eichler; N Lubenow; H Kwasny; M Luz
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

8.  Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay.

Authors:  A Greinacher; J Amiral; V Dummel; A Vissac; V Kiefel; C Mueller-Eckhardt
Journal:  Transfusion       Date:  1994-05       Impact factor: 3.157

9.  Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides.

Authors:  A Greinacher; I Michels; U Liebenhoff; P Presek; C Mueller-Eckhardt
Journal:  Br J Haematol       Date:  1993-08       Impact factor: 6.998

Review 10.  Heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  Annu Rev Med       Date:  1989       Impact factor: 13.739

View more
  2 in total

Review 1.  Heparin-induced thrombocytopenia in the ICU: an overview.

Authors:  Yasser Sakr
Journal:  Crit Care       Date:  2011-03-22       Impact factor: 9.097

2.  Dabigatran, a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia.

Authors:  Ahmad Mirdamadi
Journal:  ARYA Atheroscler       Date:  2013-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.